
  
    
      
        Background_NNP
        Although_IN there_EX have_VBP been_VBN major_JJ developments_NNS in_IN its_PRP$
        diagnosis_NN and_CC treatment_NN ,_, the_DT mortality_NN rate_NN of_IN septic_JJ shock_NN
        has_VBZ progressively_RB increased_VBN over_IN the_DT past_JJ few_JJ decades_NNS ._. The_DT
        mortality_NN rate_NN can_MD be_VB as_RB high_JJ as_IN 60_CD -_: 70_CD %_NN in_IN cases_NNS with_IN
        multi-organ_JJ failure_NN [_NN 1_CD ]_NN ,_, and_CC several_JJ pharmacological_JJ
        agents_NNS have_VBP been_VBN used_VBN in_IN an_DT effort_NN to_TO reduce_VB this_DT
        percentage_NN [_NN 2_CD ]_NN ._.
        In_IN endotoxic_JJ shock_NN ,_, bacterial_JJ endotoxin_NN enters_VBZ the_DT
        systemic_JJ circulation_NN and_CC triggers_VBZ the_DT release_NN of_IN
        pro-inflammatory_JJ mediators_NNS ._. Prostaglandin_NNP is_VBZ released_VBN
        during_IN inflammatory_JJ reactions_NNS ,_, causing_VBG an_DT increase_NN in_IN
        microvascular_NN hydrostatic_JJ pressure_NN ,_, which_WDT is_VBZ a_DT primary_JJ
        cause_NN of_IN edema_NN and_CC a_DT contributory_NN factor_NN in_IN hypovolemia_NN [_NN 3_CD
        4_CD ]_NN ._.
        Non-steroidal_NNP anti-inflammatory_JJ agents_NNS (_( NSAIDs_NNP )_) ,_, such_JJ as_IN
        acetyl_NN salicylic_JJ acid_NN and_CC indometasin_NN ,_, have_VBP been_VBN used_VBN in_IN
        the_DT treatment_NN of_IN sepsis_NN and_CC septic_JJ shock_NN ,_, and_CC an_DT
        improvement_NN in_IN survival_NN has_VBZ been_VBN noted_VBN ._. Several_JJ researchers_NNS
        have_VBP also_RB evaluated_VBN ibuprofen_NN ,_, and_CC beneficial_JJ effects_NNS on_IN
        pathophysiological_JJ changes_NNS have_VBP been_VBN observed_VBN [_NN 3_CD ]_NN ._. The_DT
        first_JJ major_JJ study_NN of_IN ibuprofen_NN in_IN endotoxic_JJ shock_NN was_VBD
        performed_VBN by_IN Jacobs_NNP 
        et_CC al_NN ._. [_NN 5_CD ]_NN ._. This_DT study_NN indicated_VBD
        that_DT ibuprofen_NN can_MD limit_VB the_DT degree_NN of_IN hypotension_NN and_CC
        acidosis_NNS ,_, and_CC decrease_VB the_DT cardiac_JJ index_NN in_IN endotoxic_JJ
        shock_NN ._. Fink_NNP 
        et_CC al_NN ._. [_NN 6_CD ]_NN reported_VBD that_DT ibuprofen_NN
        restored_VBD the_DT normal_JJ hemodynamic_JJ pattern_NN ._. However_RB ,_, Hulton_NNP 
        et_CC al_NN ._. [_NN 7_CD ]_NN saw_VBD no_DT major_JJ metabolic_JJ
        effect_NN in_IN 
        E_NNP ._. coli_NNS sepsis_NN ._. Coran_NNP 
        et_CC al_NN ._. [_NN 8_CD ]_NN showed_VBD that_IN the_DT
        administration_NN of_IN ibuprofen_NN in_IN septic_JJ shock_NN in_IN dogs_NNS did_VBD not_RB
        reduce_VB cytokine_NN levels_NNS ._. Herbertson_NNP 
        et_CC al_NN ._. [_NN 9_CD ]_NN showed_VBD that_DT ibuprofen_NN
        administration_NN in_IN endotoxic_JJ shock_NN in_IN pigs_NNS could_MD prevent_VB the_DT
        early_JJ hemodynamic_JJ changes_NNS following_VBG entotoxemia_NN ,_, but_CC not_RB
        the_DT later_JJ changes_VBZ ._. Bernard_NNP 
        et_CC al_NN ._. [_NN 10_CD ]_NN reported_VBD that_IN ,_, in_IN
        patients_NNS with_IN sepsis_NN ,_, treatment_NN with_IN ibuprofen_NN reduced_VBD
        levels_NNS of_IN prostacylin_NN and_CC thromboxane_NN and_CC decreased_VBD fever_NN ,_,
        tachycardia_NN ,_, oxygen_NN consumption_NN ,_, and_CC lactic_JJ acidosis_NNS ,_, but_CC
        did_VBD not_RB prevent_VB the_DT development_NN of_IN shock_NN or_CC acute_JJ
        respiratory_JJ distress_NN syndrome_NN ,_, and_CC did_VBD not_RB improve_VB
        survival_NN ._.
        Despite_IN several_JJ studies_NNS using_VBG ibuprofen_NN in_IN endotoxic_JJ and_CC
        septic_JJ shock_NN models_NNS ,_, there_EX are_VBP some_DT conflicting_JJ results_NNS
        with_IN respect_NN to_TO survival_NN ,_, and_CC there_EX are_VBP few_JJ studies_NNS using_VBG
        pre-treatment_JJ with_IN ibuprofen_NN ._. In_IN this_DT study_NN ,_, we_PRP
        investigated_VBD the_DT effects_NNS of_IN ibuprofen_NN on_IN physiological_JJ
        parameters_NNS and_CC survival_NN in_IN pre-_NN and_CC post-treated_JJ rabbits_NNS
        with_IN experimentally_RB induced_VBN endotoxic_JJ shock_NN ._.
      
      
        Methods_NNP
        
          Preparation_NNP of_IN animals_NNS
          Twenty-eight_NNP New_NNP Zealand_NNP rabbits_NNS were_VBD anaesthetized_JJ by_IN
          intramuscular_NN (_( I_NN ._. M_NNP ._. )_) injection_NN with_IN 35_CD mg_NN /_NN kg_NN ketamin_NN
          hydrochloride_NN (_( Ketalar_NNP ampul_NN ,_, 50_CD g_SYM /_NN ml_NN ,_, Eczacibasi_NNP Drug_NNP
          Company_NNP ,_, Istanbul_NNP ,_, Turkey_NNP )_) and_CC 5_CD mg_NN /_NN kg_NN xylasine_NN
          hydrochloride_NN (_( Rompun_NNP ampul_NN ,_, 23_CD ._. 32_CD mg_NN /_NN ml_NN ,_, Bayer_NNP ,_,
          Istanbul_NNP ,_, Turkey_NNP )_) ._. Anesthesia_NNP was_VBD maintained_VBN with_IN
          additional_JJ doses_NNS of_IN ketamin_NN and_CC xylasine_NN ._. 24_CD G_NNP canulas_NNS
          were_VBD inserted_VBN in_IN to_TO the_DT right_JJ femoral_NN artery_NN and_CC vein_NN and_CC
          monitored_VBN with_IN a_DT Siemens_NNP SC_NNP 6000_CD monitor_VB (_( Danvers_NNP ,_, MA_NNP ,_,
          USA_NNP )_) ._.
        
        
          Study_NNP Design_NNP
          The_DT rabbits_NNS were_VBD randomly_RB divided_VBN into_IN four_CD groups_NNS of_IN
          seven_CD animals_NNS ._. In_IN Group_NNP I_PRP (_( control_NN )_) ,_, 1_CD mL_NN isotonic_JJ saline_NN
          was_VBD given_VBN by_IN intravenous_JJ infusion_NN and_CC 1_CD mL_NN blood_NN samples_NNS
          (_( to_TO obtain_VB basal_NN vital_JJ measurements_NNS and_CC biochemical_JJ
          parameters_NNS )_) were_VBD taken_VBN simultaneously_RB at_IN 0_CD ,_, 30_CD ,_, 60_CD ,_, 90_CD ,_,
          120_CD ,_, 180_CD ,_, and_CC 240_CD minutes_NNS ._. The_DT rabbits_NNS in_IN Groups_NNS II_NNP ,_, III_NNP
          and_CC IV_NNP (_( study_NN groups_NNS )_) received_VBD 1_CD mL_NN sterile_JJ saline_NN at_IN 30_CD
          minute_NN intervals_NNS for_IN 120_CD minutes_NNS ,_, after_IN which_WDT the_DT
          sampling_VBG and_CC injection_NN frequency_NN was_VBD increased_VBN to_TO every_DT
          60_CD minutes_NNS ._. Sterile_NNP saline_NN was_VBD given_VBN to_TO Group_NNP I_PRP for_IN the_DT
          duration_NN of_IN the_DT experiment_NN ,_, including_VBG at_IN t_NN 
          0_CD ._. Group_NNP II_NNP received_VBD 2_CD mg_NN /_NN kg_NN
          endotoxin_NN (_( 
          Escherichia_NNP coli_NNS O_NNP 55_CD :_: B_NNP 5_CD ,_, Sigma_NNP
          Chemical_NNP Company_NNP ,_, USA_NNP )_) in_IN sterile_JJ physiological_JJ saline_NN
          (_( 0_CD ._. 5_LS mL_NN /_NN kg_NN )_) at_IN t_NN 
          0_CD ._. Sodium_NNP salt_NN of_IN ibuprofen_NN (_( Sigma_NNP
          Chemical_NNP Company_NNP ,_, USA_NNP )_) was_VBD dissolved_VBN in_IN sterile_JJ saline_NN at_IN
          77_CD °_NN C_NNP in_IN a_DT hot_JJ water_NN bath_NN ._. It_PRP was_VBD cooled_VBN down_IN to_TO 35_CD -_: 37_CD °_NN C_NNP ,_,
          then_RB injected_VBN into_IN Groups_NNS III_NNP and_CC IV_NNP by_IN slow_JJ infusion_NN at_IN
          a_DT dose_NN of_IN 30_CD mg_NN /_NN kg_NN /_NN 5_CD mL_NN at_IN +_NN 30_CD and_CC -_: 30_CD minutes_NNS ,_,
          respectively_RB ._. Rabbits_NNP in_IN the_DT first_JJ group_NN were_VBD followed_VBN
          for_IN 240_CD minutes_NNS ,_, and_CC those_DT in_IN the_DT remaining_VBG groups_NNS were_VBD
          followed_VBN until_IN they_PRP died_VBD ._.
        
        
          Measurements_NNP
          Complete_JJ blood_NN counts_VBZ (_( CBC_NNP )_) were_VBD measured_VBN with_IN an_DT
          S_NNP +_NN Coulter_NNP Counter_NNP (_( Fullerton_NNP ,_, CA_NNP ,_, USA_NNP )_) ._. Blood_NNP samples_NNS for_IN
          measuring_VBG Thromboxane_NNP B_NNP 
          2_CD (_( TxB_NNP 
          2_LS )_) levels_NNS were_VBD collected_VBN in_IN
          EDTA-tubes_NNP ,_, centrifuged_JJ at_IN 2000_CD rpm_NN for_IN 20_CD minutes_NNS ,_, and_CC
          immediately_RB stored_VBD at_IN -_: 20_CD °_NN C_NNP ._. Urine_NNP samples_NNS were_VBD collected_VBN
          for_IN Prostaglandin_NNP E_NNP 
          2_CD (_( PGE_NNP 
          2_LS )_) measurements_NNS by_IN suprapubic_JJ
          aspiration_NN ,_, which_WDT completely_RB emptied_VBN the_DT bladder_NN ._. The_DT
          urine_NN samples_NNS were_VBD immediately_RB stored_VBN at_IN -_: 20_CD °_NN C_NNP ._. TxB_NNP 
          2_CD and_CC PGE_NNP 
          2_CD were_VBD determined_VBN by_IN radioimmunoassay_NN
          according_VBG to_TO the_DT manufacturer_NN 's_POS protocol_NN (_( Amersham_NNP
          Pharmacia_NNP Biotech_NNP Ltd_NNP ,_, UK_NNP )_) using_VBG the_DT Amerlex-_NNP M_NNP Magnetic_JJ
          Separation_NNP System_NNP at_IN the_DT Department_NNP of_IN Biochemistry_NNP ,_,
          College_NNP of_IN Medicine_NNP ,_, Istanbul_NNP University_NNP ._. Rectal_NNP
          temperatures_NNS were_VBD taken_VBN with_IN a_DT thermometer_NN ._.
        
        
          Statistical_NNP Analysis_NNP
          All_DT data_NNS are_VBP presented_VBN as_IN mean_NN ±_NN SEM_NNP ._. Parameters_NNP were_VBD
          compared_VBN over_IN the_DT study_NN period_NN using_VBG analysis_NN of_IN variance_NN
          for_IN repeated_VBN measures_NNS (_( SPSS_NNP version_NN 10_CD ._. 01_CD for_IN Windows_NNP )_) ._.
          Where_WRB the_DT F_NN values_NNS were_VBD found_VBN to_TO be_VB significant_JJ ,_, data_NNS
          were_VBD compared_VBN with_IN Tukey_NNP 's_POS b_SYM test_NN ._. Comparisons_NNP between_IN
          the_DT four_CD groups_NNS at_IN the_DT same_JJ time_NN point_NN were_VBD analyzed_VBN by_IN
          one-way_JJ analysis_NN of_IN variance_NN followed_VBN by_IN Tukey_NNP '_POS s-b_JJ post_NN
          hoc_FW test_NN ,_, where_WRB appropriate_JJ ._. P_NN <_NN 0_CD ._. 05_CD was_VBD considered_VBN
          statistically_RB significant_JJ ._.
        
      
      
        Results_NNS
        
          Respiratory_JJ rate_NN
          This_DT was_VBD significantly_RB increased_VBN over_IN 30_CD ,_, 60_CD ,_, 90_CD and_CC
          120_CD minutes_NNS in_IN group_NN II_NNP (_( p_NN <_NN 0_CD ._. 001_CD )_) ._. In_IN comparison_NN ,_, it_PRP
          was_VBD high_JJ at_IN 30_CD minutes_NNS ,_, but_CC returned_VBD to_TO t_NN 
          0_CD levels_NNS after_IN 60_CD min_NN in_IN group_NN III_NNP
          rabbits_NNS ._.
          The_DT respiratory_JJ rate_NN in_IN Group_NNP IV_NNP was_VBD increased_VBN
          compared_VBN to_TO the_DT control_NN group_NN (_( Group_NNP I_PRP )_) ,_, but_CC this_DT
          difference_NN was_VBD not_RB statistically_RB significant_JJ (_( p_NN >_NN
          0_CD ._. 05_CD )_) ._. This_DT parameter_NN in_IN both_DT Groups_NNS III_NNP and_CC IV_NNP was_VBD lower_JJR
          than_IN in_IN Group_NNP II_NNP (_( p_NN <_NN 0_CD ._. 001_CD )_) ._. There_EX was_VBD no_DT significant_JJ
          difference_NN in_IN respiratory_JJ rate_NN between_IN Groups_NNS III_NNP and_CC IV_NNP
          (_( p_NN >_NN 0_CD ._. 05_CD ,_, Table_NNP 1_CD and_CC Fig_NNP ._. 1_LS )_) ._.
        
        
          Heart_NNP rate_NN
          In_IN Group_NNP II_NNP rabbits_NNS ,_, which_WDT received_VBD endotoxin_NN ,_, heart_NN
          rates_NNS significantly_RB increased_VBN between_IN 30_CD and_CC 90_CD minutes_NNS ,_,
          compared_VBN to_TO t_NN 
          0_CD (_( p_NN <_NN 0_CD ._. 001_CD )_) ._.
          Group_NNP III_NNP received_VBD endotoxin_NN and_CC ibuprofen_NN at_IN 0_CD and_CC 30_CD
          minutes_NNS ,_, respectively_RB ._. In_IN this_DT group_NN ,_, heart_NN rates_NNS were_VBD
          found_VBN to_TO be_VB increased_VBN at_IN 30_CD and_CC 60_CD minutes_NNS compared_VBN to_TO t_NN 
          0_CD (_( p_NN >_NN 0_CD ._. 05_CD )_) ._. In_IN this_DT group_NN ,_, only_RB
          one_CD rabbit_NN survived_VBD after_IN 420_CD minutes_NNS ._.
          Ibuprofen_NNP was_VBD administered_VBN to_TO Group_NNP IV_NNP at_IN 30_CD min_NN and_CC
          endotoxin_NN at_IN t_NN 
          0_CD ._. An_DT increase_NN in_IN heart_NN rate_NN was_VBD
          observed_VBN at_IN 60_CD minutes_NNS ,_, but_CC this_DT was_VBD not_RB statistically_RB
          significant_JJ (_( p_NN >_NN 0_CD ._. 05_CD )_) ._.
          When_WRB all_DT groups_NNS were_VBD compared_VBN ,_, heart_NN rates_NNS at_IN 60_CD min_NN
          in_IN both_DT Groups_NNS II_NNP and_CC III_NNP were_VBD significantly_RB higher_JJR than_IN
          in_IN Group_NNP I_PRP (_( p_NN <_NN 0_CD ._. 05_CD )_) ._. Heart_NNP rates_NNS in_IN Group_NNP IV_NNP were_VBD
          not_RB significantly_RB different_JJ from_IN the_DT control_NN group_NN (_( p_NN
          >_NN 0_CD ._. 05_CD )_) ,_, but_CC were_VBD significantly_RB lower_JJR than_IN both_DT Groups_NNS
          II_NNP and_CC III_NNP (_( p_NN <_NN 0_CD ._. 01_CD ,_, Table_NNP 2_CD and_CC Fig_NNP ._. 2_LS )_) ._.
        
        
          Mean_VB arterial_NN pressure_NN
          MAP_NNP levels_NNS showed_VBD an_DT obvious_JJ decrease_NN at_IN 30_CD minutes_NNS in_IN
          group_NN II_NNP ,_, which_WDT received_VBD only_RB endotoxin_NN from_IN t_NN 
          0_CD ._. MAP_NNP levels_NNS gradually_RB decreased_VBD in_IN
          group_NN III_NNP ,_, but_CC showed_VBD a_DT more_RBR regular_JJ gradual_JJ decrease_NN in_IN
          group_NN IV_NNP ._.
          When_WRB MAP_NNP levels_NNS between_IN the_DT groups_NNS were_VBD compared_VBN ,_, it_PRP
          was_VBD observed_VBN that_IN groups_NNS II_NNP and_CC III_NNP had_VBD statistically_RB
          significant_JJ decreases_NNS compared_VBN to_TO groups_NNS I_PRP and_CC IV_NNP (_( p_NN <_NN
          0_CD ._. 0001_CD )_) at_IN 30_CD minutes_NNS ._. Although_IN MAP_NNP values_NNS decreased_VBD in_IN
          group_NN IV_NNP ,_, there_EX was_VBD an_DT obvious_JJ difference_NN between_IN groups_NNS
          IV_NNP and_CC I_PRP (_( p_NN >_NN 0_CD ._. 05_CD )_) ._.
          At_IN 60_CD minutes_NNS ,_, MAP_NNP levels_NNS started_VBD to_TO decrease_VB in_IN group_NN
          IV_NNP ,_, and_CC were_VBD statistically_RB different_JJ from_IN groups_NNS III_NNP and_CC
          I_PRP (_( p_NN <_NN 0_CD ._. 01_CD )_) ._. At_IN 90_CD minutes_NNS ,_, MAP_NNP levels_NNS in_IN groups_NNS II_NNP
          and_CC IV_NNP remained_VBD statistically_RB different_JJ from_IN groups_NNS I_PRP and_CC
          III_NNP (_( p_NN <_NN 0_CD ._. 01_CD )_) ._. At_IN 120_CD minutes_NNS ,_, they_PRP started_VBD to_TO
          decrease_VB in_IN group_NN III_NNP and_CC statistically_RB clear_JJ differences_NNS
          from_IN group_NN I_PRP (_( p_NN <_NN 0_CD ._. 05_CD )_) could_MD be_VB seen_VBN ._. Arterial_NNP
          pressure_NN in_IN group_NN III_NNP was_VBD found_VBN to_TO be_VB statistically_RB
          higher_JJR than_IN in_IN both_DT groups_NNS II_NNP and_CC IV_NNP (_( p_NN <_NN 0_CD ._. 02_CD )_) ._. At_IN
          180_CD and_CC 240_CD minutes_NNS ,_, MAP_NNP levels_NNS kept_VBD decreasing_VBG in_IN groups_NNS
          II_NNP ,_, III_NNP and_CC IV_NNP ._. They_PRP were_VBD clearly_RB lower_JJR in_IN those_DT three_CD
          groups_NNS than_IN in_IN group_NN I_PRP (_( p_NN <_NN 0_CD ._. 001_CD ,_, Table_NNP 3_CD and_CC Fig_NNP ._.
          3_LS )_) ._.
        
        
          Body_NN temperature_NN
          In_IN general_JJ ,_, there_EX was_VBD no_DT statistically_RB significant_JJ
          difference_NN in_IN body_NN temperature_NN between_IN the_DT study_NN groups_NNS ,_,
          but_CC there_EX was_VBD a_DT significant_JJ difference_NN between_IN Group_NNP I_PRP
          and_CC the_DT study_NN groups_NNS (_( p_NN <_NN 0_CD ._. 001_CD )_) ._. In_IN addition_NN ,_,
          hypothermia_NN developed_VBN after_IN endotoxin_NN administration_NN ._.
        
        
          White_JJ blood_NN cell_NN count_NN
          There_EX were_VBD fewer_RBR white_JJ blood_NN cells_NNS in_IN the_DT study_NN groups_NNS
          than_IN in_IN the_DT control_NN group_NN ,_, and_CC the_DT difference_NN was_VBD
          statistically_RB significant_JJ (_( p_NN <_NN 0_CD ._. 0001_CD )_) ._. There_EX was_VBD no_DT
          significant_JJ difference_NN in_IN white_JJ blood_NN cell_NN counts_VBZ between_IN
          the_DT endotoxin-_NN and_CC ibuprofen-treated_JJ groups_NNS ._.
        
        
          Platelet_NNP count_NN
          The_DT number_NN of_IN platelets_NNS decreased_VBD after_IN endotoxin_NN
          administration_NN ,_, but_CC ibuprofen_NN had_VBD no_DT effect_NN on_IN the_DT
          platelet_NN counts_NNS ._.
        
        
          Haematocrit_NNP levels_NNS
          These_DT began_VBD to_TO decrease_VB gradually_RB after_IN 90_CD min_NN in_IN
          group_NN II_NNP ,_, and_CC after_IN 180_CD min_NN in_IN group_NN III_NNP (_( when_WRB they_PRP were_VBD
          significantly_RB lower_JJR than_IN the_DT onset_NN levels_NNS )_) ._. In_IN group_NN IV_NNP
          there_EX were_VBD no_DT statistically_RB significant_JJ changes_NNS in_IN
          haematocrit_NN values_NNS throughout_IN the_DT study_NN ._.
        
        
          Plasma_NNP TxB_NNP 2_CD levels_NNS
          These_DT increased_VBN following_VBG administration_NN of_IN endotoxin_NN
          at_IN t_NN 
          0_CD in_IN Group_NNP II_NNP ._. Significant_JJ decreases_NNS
          in_IN TxB_NNP 
          2_CD levels_NNS were_VBD detected_VBN in_IN Group_NNP III_NNP
          from_IN 60_CD to_TO 240_CD min_NN ,_, after_IN injection_NN of_IN ibuprofen_NN at_IN 30_CD
          min_NN ._. Highly_NNP significant_JJ differences_NNS were_VBD observed_VBN between_IN
          the_DT t_NN 
          0_CD and_CC 240_CD min_NN samples_NNS (_( p_NN <_NN
          0_CD ._. 001_CD )_) ._.
          In_IN Group_NNP IV_NNP ,_, plasma_NN TxB_NNP 
          2_CD levels_NNS were_VBD lowest_JJS between_IN -_: 30_CD
          minutes_NNS and_CC t_NN 
          0_CD (_( there_EX was_VBD no_DT significant_JJ difference_NN
          between_IN them_PRP )_) ._. Plasma_NNP TxB_NNP 
          2_CD levels_NNS began_VBD to_TO increase_VB after_IN 30_CD
          minutes_NNS ,_, which_WDT was_VBD significantly_RB different_JJ from_IN the_DT -_: 30_CD
          minute_NN and_CC t_NN 
          0_CD values_NNS (_( p_NN <_NN 0_CD ._. 005_CD and_CC p_NN <_NN
          0_CD ._. 01_CD ,_, respectively_RB )_) ._.
          When_WRB plasma_NN TxB_NNP 
          2_CD levels_NNS were_VBD compared_VBN between_IN all_DT
          groups_NNS ,_, t_NN 
          0_CD values_NNS were_VBD not_RB significantly_RB
          different_JJ between_IN Groups_NNS II_NNP and_CC III_NNP (_( p_NN >_NN 0_CD ._. 05_CD )_) ,_, but_CC
          they_PRP were_VBD significantly_RB lower_JJR in_IN Group_NNP IV_NNP than_IN in_IN any_DT of_IN
          the_DT other_JJ groups_NNS (_( p_NN <_NN 0_CD ._. 006_CD )_) ._.
          At_IN 60_CD minutes_NNS ,_, plasma_NN TxB_NNP 
          2_CD levels_NNS were_VBD reduced_VBN in_IN both_DT Groups_NNS
          II_NNP and_CC III_NNP ,_, but_CC were_VBD increased_VBN in_IN Group_NNP IV_NNP ._. They_PRP were_VBD
          significantly_RB different_JJ between_IN Groups_NNS II_NNP and_CC III_NNP and_CC the_DT
          control_NN group_NN ,_, but_CC no_DT significant_JJ differences_NNS were_VBD
          detected_VBN between_IN study_NN groups_NNS (_( p_NN >_NN 0_CD ._. 05_CD ,_, Table_NNP 4_CD and_CC
          Fig_NNP ._. 4_LS )_) ._.
        
        
          Urine_NNP PGE_NNP 2_CD levels_NNS
          These_DT increased_VBN transiently_RB after_IN 30_CD minutes_NNS in_IN Group_NNP
          II_NNP ,_, and_CC the_DT increase_NN at_IN 60_CD min_NN was_VBD significantly_RB
          different_JJ from_IN the_DT 90_CD min_NN sample_NN ._. In_IN Group_NNP III_NNP ,_, urine_NN PGE_NNP
          
          2_LS levels_NNS were_VBD significantly_RB increased_VBN
          at_IN 30_CD min_NN compared_VBN with_IN t_NN 
          0_CD (_( p_NN <_NN 0_CD ._. 001_CD )_) ._. However_RB ,_, they_PRP
          declined_VBD after_IN 60_CD minutes_NNS ._. This_DT decline_NN continued_VBD to_TO the_DT
          90_CD minute_NN sample_NN ,_, so_IN that_IN PGE_NNP 
          2_CD levels_NNS at_IN both_DT 60_CD and_CC 90_CD min_NN were_VBD
          significantly_RB lower_JJR than_IN the_DT 30_CD minute_NN value_NN (_( p_NN <_NN
          0_CD ._. 001_CD )_) ,_, but_CC no_DT different_JJ from_IN t_NN 
          0_CD (_( p_NN >_NN 0_CD ._. 05_CD )_) ._. In_IN Group_NNP IV_NNP ,_, PGE_NNP 
          2_CD levels_NNS increased_VBN at_IN 30_CD min_NN compared_VBN
          to_TO t_NN 
          0_CD ,_, after_IN administration_NN of_IN endotoxin_NN ._.
          They_PRP then_RB began_VBD to_TO decrease_VB from_IN 60_CD and_CC 120_CD min_NN ,_, but_CC the_DT
          difference_NN was_VBD only_RB significant_JJ between_IN 30_CD and_CC 90_CD min_NN (_( p_NN
          <_NN 0_CD ._. 025_CD ,_, Table_NNP 5_CD and_CC Fig_NNP ._. 5_LS )_) ._.
        
        
          Survival_NNP rates_NNS
          Among_IN the_DT three_CD endotoxic_JJ shock_NN groups_NNS ,_, the_DT longest_JJS
          mean_NN survival_NN time_NN was_VBD observed_VBN in_IN Group_NNP IV_NNP (_( 383_CD ._. 0_CD ±_NN 39_CD ._. 0_CD
          minutes_NNS )_) ._. The_DT survival_NN rate_NN in_IN Group_NNP IV_NNP was_VBD significantly_RB
          higher_JJR than_IN in_IN Group_NNP II_NNP (_( 192_CD ._. 9_CD ±_NN 46_CD ._. 9_CD minutes_NNS )_) ,_, but_CC not_RB
          significantly_RB higher_JJR than_IN Group_NNP III_NNP (_( 339_CD ._. 1_LS ±_NN 33_CD ._. 5_LS
          minutes_NNS )_) (_( p_NN >_NN 0_CD ._. 05_CD )_) ._. In_IN Group_NNP III_NNP ,_, mean_VB survival_NN time_NN
          was_VBD also_RB significantly_RB higher_JJR than_IN in_IN Group_NNP II_NNP (_( p_NN <_NN
          0_CD ._. 05_CD )_) ._. Mean_VB survival_NN times_NNS are_VBP shown_VBN in_IN Fig_NNP ._. 6_CD ._.
        
      
      
        Discussion_NNP
        Ibuprofen_NNP is_VBZ a_DT reversible_JJ ,_, short-acting_JJ cyclooxygenase_NN
        inhibitor_NN ,_, which_WDT particularly_RB blocks_VBZ the_DT synthesis_NN of_IN
        thromboxane_NN ._. Under_IN 
        in_IN vitro_NN conditions_NNS ,_, it_PRP has_VBZ been_VBN
        shown_VBN that_DT ibuprofen_NN stabilizes_VBZ lyszomal_NN membranes_NNS ,_,
        restrains_NNS the_DT secretion_NN of_IN lysozomal_NN enzymes_NNS from_IN
        granulocytes_NNS ,_, and_CC prevents_VBZ the_DT aggregation_NN of_IN platelets_NNS as_RB
        well_RB as_IN the_DT immigration_NN of_IN leukocytes_NNS [_NN 1_CD 2_CD 3_CD 4_CD 5_CD ]_NN ._.
        NSAIDs_NNP were_VBD first_RB used_VBN by_IN Northover_NNP and_CC Subramanian_NNP [_NN 11_CD
        ]_NN in_IN an_DT endotoxic_JJ shock_NN model_NN in_IN dogs_NNS ,_, in_IN order_NN to_TO improve_VB
        hemodynamic_JJ disorders_NNS ._. In_IN endotoxic_JJ or_CC septic_JJ shock_NN models_NNS ,_,
        respiration_NN pathway_NN changes_NNS occur_VBP in_IN the_DT lungs_NNS ._. Metabolites_NNP
        of_IN cyclooxygenase_NN play_VBP an_DT important_JJ role_NN in_IN this_DT ._. Studies_NNS
        done_VBN with_IN ARDS_NNP patients_NNS have_VBP shown_VBN that_IN there_EX is_VBZ an_DT
        increase_NN in_IN the_DT number_NN of_IN PMNs_NNP in_IN the_DT lung_NN and_CC
        bronco-alveolar_JJ fluid_NN ,_, which_WDT cause_VBP an_DT increase_NN in_IN elastase_NN
        and_CC other_JJ lysozomal_NN enzymes_NNS [_NN 12_CD ]_NN ._. Kopolovic_NNP 
        et_CC al_NN ._. [_NN 13_CD ]_NN have_VBP reported_VBN that_DT
        respiration_NN dysfunction_NN and_CC hypoxemia_NN were_VBD improved_VBN and_CC
        pulmonary_JJ hypertension_NN decreased_VBD in_IN pigs_NNS that_WDT were_VBD
        administered_VBN ibuprofen_NN after_IN 
        Pseudomonas_NNP aeruginosa_NN infusion_NN ._. In_IN
        addition_NN ,_, the_DT same_JJ researchers_NNS reported_VBD that_DT treatment_NN with_IN
        ibuprofen_NN caused_VBD a_DT decrease_NN in_IN pulmonary_JJ shunt_NN and_CC lung_NN
        edema_NN ._. Balk_NNP 
        et_CC al_NN ._. [_NN 14_CD ]_NN used_VBD ibuprofen_NN in_IN a_DT
        canine_JJ endotoxic_JJ shock_NN model_NN and_CC found_VBD that_IN it_PRP affected_VBD the_DT
        extent_NN of_IN histological_JJ and_CC morphometric_JJ lung_NN injury_NN ._.
        In_IN this_DT study_NN ,_, the_DT respiratory_JJ rates_NNS of_IN the_DT study_NN groups_NNS
        were_VBD significantly_RB higher_JJR than_IN the_DT control_NN group_NN at_IN 30_CD min_NN ._.
        The_DT respiration_NN rates_NNS in_IN both_DT Groups_NNS III_NNP and_CC IV_NNP were_VBD lower_JJR
        than_IN in_IN Group_NNP II_NNP right_NN out_IN to_TO 360_CD minutes_NNS ._. Because_IN the_DT
        study_NN groups_NNS (_( II_NNP ,_, III_NNP ,_, and_CC IV_NNP )_) showed_VBD no_DT remarkable_JJ
        differences_NNS after_IN 360_CD min_NN ,_, we_PRP presume_NN that_DT ibuprofen_NN is_VBZ not_RB
        effective_JJ after_IN this_DT time_NN ._. In_IN addition_NN ,_, ibuprofen_NN
        administration_NN can_MD prevent_VB hyperpnoea_NN if_IN given_VBN before_IN
        endotoxin_NN ._.
        Endotoxin_NNP administration_NN may_MD lead_VB to_TO hypotension_NN and_CC
        tachycardia_NN [_NN 1_CD ]_NN ._. In_IN one_CD study_NN ,_, Suffredini_NNP 
        et_CC al_NN ._. [_NN 15_CD ]_NN administered_VBN endotoxin_NN
        to_TO healthy_JJ volunteers_NNS and_CC observed_VBD an_DT increase_NN in_IN cardiac_JJ
        output_NN of_IN 53_CD %_NN ,_, a_DT decrease_NN in_IN systemic_JJ vascular_NN pressure_NN of_IN
        46_CD %_NN and_CC an_DT increase_NN in_IN heart_NN rate_NN of_IN 36_CD %_NN ._. Previously_RB ,_, it_PRP
        has_VBZ been_VBN observed_VBN that_DT ibuprofen_NN administration_NN in_IN
        endotoxic_JJ shock_NN models_NNS prevents_VBZ an_DT increase_NN in_IN heart_NN rate_NN
        due_JJ to_TO metabolic_JJ changes_NNS or_CC regulation_NN of_IN oxygen_NN dispersal_NN
        at_IN the_DT tissue_NN level_NN [_NN 16_CD 17_CD ]_NN ._. In_IN addition_NN ,_, another_DT study_NN
        by_IN Revhaug_NNP 
        et_CC al_NN ._. [_NN 18_CD ]_NN reported_VBD that_DT ibuprofen_NN
        administration_NN before_IN endotoxin_NN prevented_VBD an_DT increase_NN in_IN
        heart_NN rate_NN ._. Yamanaka_NNP 
        et_CC al_NN ._. [_NN 19_CD ]_NN reported_VBD that_IN there_EX
        were_VBD no_DT significant_JJ differences_NNS from_IN the_DT heart_NN rates_NNS of_IN
        controls_NNS in_IN a_DT similar_JJ study_NN ._.
        In_IN our_PRP$ study_NN ,_, it_PRP was_VBD observed_VBN that_IN pre-treatment_JJ with_IN
        ibuprofen_NN prevented_VBD heart_NN rate_NN increase_NN ._. The_DT effects_NNS of_IN
        ibuprofen_NN started_VBD at_IN 90_CD min_NN and_CC lasted_VBD up_IN to_TO 180_CD min_NN in_IN the_DT
        group_NN that_WDT received_JJ ibuprofen_NN after_IN endotoxin_NN ._. Thus_RB ,_, it_PRP
        appears_VBZ that_DT ibuprofen_NN has_VBZ no_DT effect_NN on_IN secreted_JJ
        cyclooxygenase_NN products_NNS ,_, as_IN it_PRP inhibits_NNS the_DT cyclooxygenase_NN
        enzyme_NN ._. With_IN this_DT inhibition_NN ,_, new_JJ production_NN of_IN
        cyclooxygenase_NN products_NNS is_VBZ blocked_VBN ._. Therefore_RB ,_, the_DT
        cyclooxygenase_NN secreted_JJ by_IN Group_NNP III_NNP caused_VBD tachycardia_NN ,_,
        but_CC new_JJ formation_NN of_IN cyclooxygenase_NN was_VBD inhibited_VBD by_IN
        ibuprofen_NN administration_NN ,_, so_RB tachycardia_NN was_VBD resolved_VBN ._.
        Therefore_RB ,_, it_PRP seems_VBZ that_DT ibuprofen_NN administration_NN has_VBZ
        little_JJ effect_NN on_IN respiratory_JJ rate_NN and_CC heart_NN rate_NN ._.
        Beck_NNP and_CC Abel_NNP [_NN 20_CD ]_NN reported_VBD that_DT administration_NN of_IN
        ibuprofen_NN before_IN endotoxin_NN blocked_VBD the_DT sudden_JJ drop_NN in_IN mean_NN
        arterial_NN pressure_NN in_IN experimentally-induced_JJ endotoxic_JJ shock_NN
        in_IN dogs_NNS ._. Coran_NNP 
        et_CC al_NN ._. [_NN 8_CD ]_NN reported_VBD that_WDT mean_VBP
        arterial_NN pressure_NN was_VBD significantly_RB higher_JJR in_IN animals_NNS that_WDT
        received_JJ ibuprofen_NN before_IN induced_VBN shock_NN than_IN the_DT control_NN
        group_NN in_IN their_PRP$ experimental_JJ canine_JJ septic_JJ shock_NN model_NN ._. They_PRP
        indicated_VBD that_IN MAP_NNP was_VBD consistently_RB about_IN 90_CD %_NN of_IN the_DT
        initial_JJ arterial_NN pressure_NN level_NN ._. They_PRP also_RB reported_VBD that_IN
        when_WRB animals_NNS received_VBD ibuprofen_NN after_IN endotoxin_NN ;_: arterial_NN
        pressure_NN initially_RB fell_VBD to_TO about_IN 50_CD %_NN ,_, then_RB increased_VBN
        gradually_RB and_CC continued_VBD to_TO be_VB about_IN 70_CD %_NN of_IN initial_JJ
        levels_NNS ._.
        In_IN the_DT present_JJ study_NN ,_, there_EX was_VBD a_DT general_JJ reduction_NN in_IN
        mean_NN arterial_NN blood_NN pressure_NN in_IN group_NN II_NNP ,_, which_WDT received_VBD
        endotoxin_NN ._. On_IN the_DT other_JJ hand_NN ,_, there_EX was_VBD a_DT sudden_JJ drop_NN in_IN
        MAP_NNP in_IN Group_NNP IV_NNP ,_, which_WDT received_VBD ibuprofen_NN before_IN endotoxin_NN ,_,
        whereas_IN an_DT increase_NN in_IN MAP_NNP was_VBD seen_VBN at_IN 60_CD minutes_NNS in_IN the_DT
        group_NN that_WDT received_JJ ibuprofen_NN after_IN endotoxin_NN ._. However_RB ,_,
        since_IN initial_JJ MAP_NNP levels_NNS were_VBD not_RB established_VBN in_IN the_DT study_NN
        groups_NNS ,_, it_PRP is_VBZ possible_JJ that_IN some_DT other_JJ mediators_NNS were_VBD
        affecting_VBG blood_NN pressure_NN at_IN the_DT start_NN of_IN the_DT
        experiment_NN ._.
        Ebong_NNP 
        et_CC al_NN ._. [_NN 21_CD ]_NN reported_VBD that_IN all_DT mice_NNS
        developed_VBD hypothermia_NN in_IN their_PRP$ model_NN ,_, where_WRB septic_JJ shock_NN
        was_VBD induced_VBN by_IN caecal_NN ligation_NN ._. While_IN body_NN temperature_NN was_VBD
        above_IN 34_CD °_NN C_NNP on_IN day_NN 1_CD ,_, it_PRP later_RB decreased_VBD below_IN 34_CD °_NN C_NNP ._. Haupt_NNP 
        et_CC al_NN ._. [_NN 22_CD ]_NN observed_VBD that_DT fever_NN in_IN
        severe_JJ septic_JJ shock_NN patients_NNS '_POS was_VBD reduced_VBN after_IN ibuprofen_NN
        administration_NN ._. However_RB ,_, they_PRP did_VBD not_RB see_VB a_DT reduction_NN in_IN
        PGE_NNP 
        2_CD levels_NNS ,_, so_IN they_PRP assumed_VBD that_IN the_DT
        reduction_NN in_IN fever_NN was_VBD due_JJ to_TO ibuprofen_NN causing_VBG a_DT decrease_NN
        in_IN IL-_NNP 1_CD and_CC TNF_NNP secretion_NN ,_, or_CC due_JJ to_TO the_DT direct_JJ effect_NN of_IN
        ibuprofen_NN on_IN the_DT central_JJ nervous_JJ system_NN ._. The_DT anti-pyretic_JJ
        effect_NN of_IN ibuprofen_NN started_VBD at_IN 4_CD hours_NNS ,_, and_CC lasted_VBD up_IN to_TO 24_CD
        hours_NNS after_IN infusion_NN ._.
        The_DT role_NN of_IN cytokines_NNS in_IN hypothermia_NN is_VBZ not_RB yet_RB known_VBN ,_,
        however_RB ,_, it_PRP is_VBZ thought_VBN that_IN the_DT decrease_NN in_IN body_NN
        temperature_NN is_VBZ dependent_JJ on_IN a_DT decrease_NN in_IN pyrojenic_JJ
        cytokines_NNS ._. During_IN hypothermic_JJ sepsis_NN ,_, the_DT response_NN of_IN
        cytokines_NNS and_CC eicosanoids_NNS is_VBZ higher_JJR than_IN in_IN febrile_NN
        patients_NNS ._. Therefore_RB ,_, ibuprofen_NN has_VBZ been_VBN considered_VBN to_TO be_VB
        more_RBR useful_JJ in_IN hypothermic_JJ patients_NNS than_IN in_IN septic_JJ shock_NN
        patients_NNS [_NN 23_CD ]_NN ._. In_IN our_PRP$ study_NN ,_, changes_NNS in_IN body_NN temperature_NN
        among_IN study_NN groups_NNS were_VBD not_RB statistically_RB significant_JJ ._.
        The_DT numbers_NNS of_IN white_JJ blood_NN cells_NNS are_VBP reduced_VBN in_IN
        experimental_JJ animals_NNS induced_VBN with_IN endotoxic_JJ shock_NN [_NN 24_CD ]_NN ._.
        Griffin_NNP 
        et_CC al_NN ._. [_NN 4_CD ]_NN reported_VBD that_IN the_DT number_NN
        of_IN white_JJ blood_NN cells_NNS decreased_VBD after_IN endotoxin_NN
        administration_NN in_IN pigs_NNS ._. In_IN addition_NN ,_, they_PRP found_VBD significant_JJ
        differences_NNS between_IN endotoxin_NN and_CC endotoxin_NN plus_CC ibuprofen_NN
        administration_NN ._. In_IN our_PRP$ study_NN groups_NNS ,_, the_DT numbers_NNS of_IN white_JJ
        blood_NN cells_NNS were_VBD significantly_RB lower_JJR than_IN in_IN the_DT controls_NNS
        (_( p_NN <_NN 0_CD ._. 0001_CD )_) ._. There_EX were_VBD ,_, however_RB ,_, no_DT significant_JJ
        differences_NNS in_IN the_DT white_JJ blood_NN cell_NN counts_VBZ between_IN
        endotoxin_NN and_CC ibuprofen_NN treated_VBD groups_NNS ._.
        Haematocrit_NNP values_NNS appear_VBP to_TO increase_VB in_IN some_DT endotoxic_JJ
        shock_NN models_NNS ,_, but_CC decrease_VB in_IN others_NNS [_NN 10_CD 19_CD 20_CD 22_CD ]_NN ._. It_PRP
        has_VBZ been_VBN reported_VBN that_DT ibuprofen_NN has_VBZ no_DT effect_NN on_IN the_DT
        consumption_NN of_IN systemic_JJ complement_VB ,_, thrombocytopenia_NN ,_,
        leucocytosis_NNS or_CC leucopenia_NN [_NN 25_CD ]_NN ._. In_IN our_PRP$ study_NN ,_, there_EX was_VBD
        no_DT increase_NN in_IN haematocrit_NN levels_NNS ._. This_DT may_MD be_VB related_VBN to_TO
        the_DT fact_NN that_IN 30_CD -_: 35_CD mL_NN of_IN blood_NN was_VBD withdrawn_VBN from_IN each_DT
        rabbit_NN ._. Ibuprofen_NNP also_RB appeared_VBD to_TO have_VB no_DT effect_NN on_IN
        haematocrit_NN levels_NNS in_IN our_PRP$ study_NN ._.
        The_DT occurrence_NN of_IN isolated_VBN thrombocytopenia_NN is_VBZ higher_JJR
        than_IN 50_CD %_NN in_IN septic_JJ shock_NN patients_NNS without_IN disseminated_VBN
        intravascular_NN coagulation_NN [_NN 26_CD ]_NN ._. The_DT endotoxic_JJ shock_NN
        experimentally_RB induced_VBN by_IN Griffin_NNP 
        et_CC al_NN ._. [_NN 4_CD ]_NN in_IN pigs_NNS showed_VBD that_IN the_DT
        numbers_NNS of_IN platelets_NNS decreased_VBD after_IN endotoxin_NN
        administration_NN ,_, but_CC no_DT significant_JJ differences_NNS were_VBD again_RB
        seen_VBN between_IN endotoxin_NN and_CC endotoxin_NN plus_CC ibuprofen_NN (_( p_NN >_NN
        0_CD ._. 05_CD )_) ._. In_IN our_PRP$ study_NN ,_, it_PRP was_VBD also_RB observed_VBN that_IN the_DT number_NN
        of_IN platelets_NNS decreased_VBD after_IN endotoxin_NN administration_NN ,_,
        whilst_NN ibuprofen_NN had_VBD no_DT effect_NN ._. Many_JJ studies_NNS have_VBP shown_VBN
        that_DT endotoxin_NN administration_NN can_MD result_VB in_IN an_DT acute_JJ
        decrease_NN in_IN the_DT white_JJ blood_NN cell_NN count_NN [_NN 4_CD 12_CD ]_NN ,_, but_CC we_PRP
        propose_VBP that_DT ibuprofen_NN has_VBZ no_DT effect_NN on_IN leukocyte_NN and_CC
        platelet_NN counts_NNS ._.
        It_PRP has_VBZ been_VBN indicated_VBN that_IN the_DT pathway_NN of_IN cyclooxygenase_NN
        products_NNS ,_, such_JJ as_IN TxB_NNP 
        2_CD and_CC PGE_NNP 
        2_CD ,_, increases_NNS in_IN many_JJ endotoxic_JJ shock_NN
        models_NNS and_CC plays_VBZ an_DT important_JJ role_NN in_IN a_DT number_NN of_IN
        pathophysiological_JJ events_NNS [_NN 21_CD 27_CD ]_NN ._.
        TxA_NNP 
        2_CD is_VBZ a_DT product_NN of_IN arachidonic_JJ acid_NN and_CC a_DT
        potent_JJ platelet_NN aggregator_NN ,_, whose_WP$ levels_NNS increase_VBP during_IN
        endotoxic_JJ shock_NN ._. Ibuprofen_NNP prevents_VBZ the_DT formation_NN of_IN TxA_NNP 
        2_CD ,_, as_RB well_RB as_IN platelet_NN and_CC leucocyte_NN
        aggregation_NN [_NN 12_CD 21_CD ]_NN ._. Fletcher_NNP 
        et_CC al_NN ._. [_NN 28_CD ]_NN reported_VBD that_IN the_DT
        levels_NNS of_IN TxB_NNP 
        2_CD were_VBD significantly_RB reduced_VBN in_IN rats_NNS by_IN
        a_DT combination_NN of_IN TNF_NNP and_CC ibuprofen_NN ._. Plasma_NNP TxB_NNP 
        2_CD levels_NNS were_VBD also_RB reduced_VBN by_IN
        introducing_VBG ibuprofen_NN into_IN the_DT faecal_NN peritonitis_NNS rat_NN model_NN
        used_VBN by_IN Wise_NNP 
        et_CC al_NN ._. [_NN 29_CD ]_NN ._.
        In_IN this_DT study_NN ,_, TxB_NNP 
        2_CD levels_NNS decreased_VBD in_IN the_DT ibuprofen_NN
        post-treated_JJ group_NN compared_VBN with_IN initial_JJ onset_NN levels_NNS ._. In_IN
        addition_NN ,_, it_PRP was_VBD found_VBN that_IN the_DT onset_NN levels_NNS of_IN TxB_NNP 
        2_CD were_VBD significantly_RB lower_JJR in_IN the_DT
        pre-treated_JJ group_NN than_IN the_DT other_JJ groups_NNS ._. Making_VBG incisions_NNS
        into_IN the_DT rabbits_NNS may_MD have_VB caused_VBN an_DT increase_NN in_IN
        pro-inflammatory_JJ cytokines_NNS ._. Low_NNP levels_NNS of_IN TxB_NNP 
        2_CD in_IN group_NN IV_NNP (_( at_IN 0_CD -_: 30_CD min_NN )_) were_VBD
        probably_RB a_DT result_NN of_IN ibuprofen_NN inhibiting_VBG the_DT increase_NN
        which_WDT would_MD normally_RB be_VB caused_VBN by_IN these_DT cytokines_NNS ._.
        The_DT endotoxic_JJ shock_NN mouse_NN model_NN reported_VBN by_IN Rosello_NNP 
        et_CC al_NN ._. [_NN 30_CD ]_NN showed_VBD that_IN the_DT levels_NNS
        of_IN PGE_NNP 
        2_CD were_VBD significantly_RB lower_JJR in_IN the_DT
        ibuprofen-treated_JJ group_NN than_IN in_IN controls_NNS ._. However_RB ,_, the_DT
        levels_NNS of_IN urine_NN PGE_NNP 
        2_CD were_VBD higher_JJR at_IN 12_CD hours_NNS in_IN both_DT
        treated_VBN and_CC untreated_JJ animals_NNS ,_, but_CC the_DT difference_NN was_VBD not_RB
        statistically_RB significant_JJ ._. In_IN our_PRP$ study_NN ,_, it_PRP was_VBD observed_VBN
        that_DT urine_NN PGE_NNP 
        2_CD gradually_RB increased_VBN in_IN group_NN II_NNP after_IN
        endotoxin_NN administration_NN ._. After_IN treatment_NN with_IN ibuprofen_NN ,_,
        urine_NN PGE_NNP 
        2_CD levels_NNS decreased_VBD over_IN the_DT next_JJ 90_CD min_NN ,_,
        but_CC later_RB began_VBD to_TO rise_VB again_RB ._. In_IN another_DT version_NN of_IN this_DT
        study_NN published_VBN previously_RB ,_, it_PRP was_VBD seen_VBN that_DT ibuprofen_NN
        reduced_VBD the_DT endothelin_NN production_NN induced_VBN by_IN endotoxin_NN
        administration_NN [_NN 31_CD ]_NN ._.
        Griffin_NNP 
        et_CC al_NN ._. [_NN 4_CD ]_NN reported_VBD that_IN there_EX was_VBD
        no_DT difference_NN in_IN mean_NN survival_NN times_NNS between_IN control_NN and_CC
        ibuprofen_NN pre-_NN and_CC post-treated_JJ groups_NNS ._. Arons_NNP 
        et_CC al_NN ._. [_NN 23_CD ]_NN performed_VBD a_DT study_NN with_IN
        hypothermic_JJ septic_JJ patients_NNS ,_, and_CC reported_VBD that_DT ibuprofen_NN
        could_MD be_VB used_VBN to_TO decrease_VB mortality_NN rates_NNS ._. Schirmer_NNP 
        et_CC al_NN ._. [_NN 32_CD ]_NN found_VBD a_DT transient_JJ
        24_CD -_: hour_NN survival_NN benefit_NN in_IN a_DT rat_NN model_NN of_IN septic_JJ shock_NN ._.
        Fletcher_NNP 
        et_CC al_NN [_NN 3_CD ]_NN also_RB reported_VBD that_IN
        TNF-induced_NNP mortality_NN could_MD be_VB reduced_VBN by_IN using_VBG ibuprofen_NN ._.
        Rosello_NNP 
        et_CC al_NN ._. [_NN 30_CD ]_NN found_VBD survival_NN rates_NNS
        increased_VBN in_IN mice_NNS treated_VBN with_IN ibuprofen_NN ._. In_IN addition_NN ,_,
        Young_NNP and_CC Passmore_NNP [_NN 33_CD ]_NN reported_VBD that_IN ibuprofen-treated_JJ
        canines_NNS with_IN induced_VBN endotoxic_JJ shock_NN had_VBD longer_JJR survival_NN
        times_NNS than_IN those_DT treated_VBN with_IN propylgallate_NN ._. However_RB ,_,
        Bernard_NNP 
        et_CC al_NN ._. [_NN 10_CD ]_NN reported_VBD that_IN there_EX
        were_VBD no_DT statistically_RB significant_JJ differences_NNS between_IN
        ibuprofen-treated_JJ and_CC untreated_JJ animals_NNS with_IN regards_VBZ to_TO
        their_PRP$ 30_CD -_: day_NN survival_NN rate_NN ._.
        In_IN our_PRP$ study_NN ,_, mean_VB survival_NN time_NN was_VBD significantly_RB
        longer_RBR in_IN the_DT ibuprofen-treated_JJ groups_NNS compared_VBN with_IN the_DT
        untreated_JJ group_NN ._. In_IN addition_NN ,_, the_DT pre-treated_JJ group_NN had_VBD a_DT
        longer_RBR mean_NN survival_NN time_NN than_IN the_DT post-treated_JJ group_NN ,_, but_CC
        it_PRP was_VBD not_RB statistically_RB significant_JJ ._.
      
      
        Conclusions_NNP
        Ibuprofen_NNP appears_VBZ to_TO increase_VB short-term_JJ survival_NN due_JJ to_TO
        its_PRP$ positive_JJ effect_NN on_IN various_JJ physiological_JJ parameters_NNS ._.
        Therefore_RB ,_, the_DT use_NN of_IN ibuprofen_NN at_IN higher_JJR doses_NNS ,_, over_IN
        longer_JJR time_NN periods_NNS ,_, or_CC in_IN combination_NN with_IN other_JJ drugs_NNS in_IN
        patients_NNS who_WP are_VBP at_IN risk_NN of_IN developing_VBG septic_JJ shock_NN could_MD
        be_VB effective_JJ as_IN a_DT prophylaxis_NNS or_CC treatment_NN ._.
      
      
        Competing_VBG Interests_NNP
        This_DT study_NN was_VBD supported_VBN by_IN Firat_NNP University_NNP Research_NNP
        Foundation_NNP ._.
      
    
  
